Amarin receives two new patent allowances related to Vascepa Amarin announced that the United States Patent and Trademark Office, or USPTO, has published notification of Notices of Allowance for Amarin's U.S. Patent Applications Serial Numbers 13/458,496 and 13/349,157. The allowed '496 and '157 applications continue to broaden our claimed methods of reducing triglycerides consistent with the FDA approved MARINE indication for Vascepa capsules through use of a pharmaceutical composition of highly pure icosapent ethyl, or EPA. A Notice of Allowance is issued after the USPTO makes a determination that a patent can be granted from an application. The issued patents would have terms that expire no earlier than in 2030. After issuance, Amarin plans to list these patents in the FDA's Approved Drug Products with Therapeutic Equivalence Evaluations, or Orange Book.
News For AMRN From The Last 14 Days
Check below for free stories on AMRN the last two weeks.